Chongqing Pharscin Pharmaceutical Co Ltd Working Capital to Net Assets Ratio

Latest as of September 2025: 50.0%

Chongqing Pharscin Pharmaceutical Co Ltd working capital to net assets ratio. Chongqing Pharscin Pharmaceutical Co Ltd (002907) has a Working Capital to Net Assets ratio of 50.0% as of September 2025. Working capital of CN¥855.56 Million (current assets of CN¥1.09 Billion minus current liabilities of CN¥233.47 Million) is measured against net assets of CN¥1.71 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 002907 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

WC/NA Ratio

50.0%
Working Capital / Net Assets

Working Capital

CN¥855.56 Million
CNY

Current Assets

CN¥1.09 Billion
CNY

Current Liabilities

CN¥233.47 Million
CNY

Working Capital to Net Assets Ratio of Chongqing Pharscin Pharmaceutical Co Ltd (2013–2024)

Working capital to net assets ratio of Chongqing Pharscin Pharmaceutical Co Ltd from 2013 to 2024. This chart shows how Chongqing Pharscin Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the ratio stands at 50.0%, reflecting working capital of CN¥855.56 Million against net assets of CN¥1.71 Billion CNY. See Chongqing Pharscin Pharmaceutical Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Chongqing Pharscin Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2013–2024)

Chongqing Pharscin Pharmaceutical Co Ltd working capital to net assets ratio by year from 2013 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Chongqing Pharscin Pharmaceutical Co Ltd from 2013 to 2024, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see balance sheet size of Chongqing Pharscin Pharmaceutical Co Ltd.

Year WC/NA Ratio Working Capital (CNY) Net Assets Current Assets Current Liabilities Change (pp)
2024 49.4% CN¥819.31 Million CN¥1.66 Billion CN¥1.03 Billion CN¥212.03 Million ▲ +5.7 pp
2023 43.6% CN¥705.96 Million CN¥1.62 Billion CN¥894.64 Million CN¥188.68 Million ▼ -2.7 pp
2022 46.3% CN¥745.63 Million CN¥1.61 Billion CN¥956.95 Million CN¥211.32 Million ▼ -8.0 pp
2021 54.3% CN¥687.13 Million CN¥1.27 Billion CN¥894.10 Million CN¥206.97 Million ▲ +0.7 pp
2020 53.6% CN¥633.21 Million CN¥1.18 Billion CN¥889.01 Million CN¥255.81 Million ▲ +0.5 pp
2019 53.1% CN¥568.39 Million CN¥1.07 Billion CN¥871.50 Million CN¥303.11 Million ▲ +13.3 pp
2018 39.8% CN¥330.02 Million CN¥828.91 Million CN¥578.99 Million CN¥248.98 Million ▼ -16.2 pp
2017 56.0% CN¥403.44 Million CN¥719.95 Million CN¥561.44 Million CN¥158.00 Million ▲ +11.4 pp
2016 44.6% CN¥205.76 Million CN¥461.42 Million CN¥396.66 Million CN¥190.91 Million ▲ +7.1 pp
2015 37.5% CN¥137.25 Million CN¥365.71 Million CN¥310.83 Million CN¥173.59 Million ▲ +3.4 pp
2014 34.2% CN¥102.42 Million CN¥299.77 Million CN¥340.04 Million CN¥237.62 Million ▲ +13.8 pp
2013 20.4% CN¥49.05 Million CN¥240.97 Million CN¥223.44 Million CN¥174.39 Million —
pp = percentage points